Captopril
What is it: A well-established ACE inhibitor targeting inflammatory and vascular dysregulation.AKA: Capoten- ⬤ Minimal research: Very little scientific study exists, with no or very few peer-reviewed studies. Insufficient data for conclusions.
- ⬤⬤ Limited research: Few studies exist, mostly small trials or case reports. Findings are preliminary and lack strong validation.
- ⬤⬤⬤ Moderately researched: Multiple studies, including mid-sized trials, exist. Some findings are replicated, but more research is needed.
- ⬤⬤⬤⬤ Well-researched: Supported by substantial evidence, including at least one large trial or meta-analysis.
- ⬤⬤⬤⬤⬤ Extensively studied: Numerous large studies and meta-analyses exist. Findings are widely accepted with strong scientific consensus.
- ⬤ Extremely Difficult to Access: Rare, experimental, or highly specialized. Requires multiple referrals, long wait times, travel, and strict follow-up.
- ⬤⬤ Difficult to Access: Limited to select centers with moderate barriers. Requires referral, potential travel, and wait times of weeks to months.
- ⬤⬤⬤ Moderately Accessible: Available in larger hospitals or clinics. Requires a basic referral, with moderate wait times and some coordination.
- ⬤⬤⬤⬤ Easy to Access: Widely available in most clinics. Minimal referral, short wait times, and simple preparation or follow-up.
- ⬤⬤⬤⬤⬤ Trivial to Access: Easily found in pharmacies or clinics. No referral needed, minimal wait, and straightforward access.
- ⬤ Up to $100
- ⬤⬤ Up to $500
- ⬤⬤⬤ Up to $2000
- ⬤⬤⬤⬤ Up to $10,000
- ⬤⬤⬤⬤⬤ More than $10,000
To calculate the reported effectiveness for a patient view, the model first analyses whether it can be ascertained that the person writing the review has had direct experience of the treatment for themselves or a loved one. If so, it then uses sentiment analysis to rate their view from 1-5 on how effective this treatment was for them, with 1 being the least effective, and 5 the most effective.
4 Research papers
Referenced in this guide
9 Patient views
Contributed in this guide
Figure out what Captopril means for you
Page contents
Basics: What you need to know
Captopril (Capoten) is a well-established angiotensin-converting enzyme (ACE) inhibitor, widely recognized for its role in treating hypertension, heart failure, and diabetic nephropathy. Recently, it has been investigated as a repurposed option for Long Covid due to its potential to address inflammatory and vascular imbalances. Though standardized dosing protocols exist for its approved uses, research is still emerging regarding its full impact on Long Covid-related symptoms.
History and development
- Snake venom roots: Captopril was inspired by peptides from the venom of the Brazilian pit viper (Bothrops jararaca), prompting researchers to explore ACE inhibition.
- Pioneering chemists: Dr. Miguel Ondetti and Dr. David Cushman at Bristol-Myers Squibb led its design and development in the late 1970s.
- First of its class: Approved by the FDA in 1981 for hypertension, it became the first ACE inhibitor on the market.
- Further expansion: Over time, its official indications broadened to include heart failure and diabetic nephropathy, demonstrating a broad therapeutic profile.
What is known
- Renin-angiotensin modulation: By reducing angiotensin II levels, it can lessen vessel constriction and inflammatory signals, potentially improving Long Covid-related fatigue and chest discomfort.
- High manufacturing standards: As an FDA-approved drug, it undergoes rigorous quality controls, resulting in consistent dosage and chemical composition.
- Potential vascular benefits: Some evidence suggests it may enhance microcirculation, which could support oxygenation and tissue repair.
- Possible symptom aggravation: Known risks like dry cough or significant drops in blood pressure can sometimes exacerbate overall discomfort if not carefully monitored.
What is not known
- Long Covid-specific efficacy: Although early case reports are encouraging, large-scale clinical trials are needed to confirm whether captopril consistently benefits individuals with Long Covid.
- Optimal dosing protocols: Standard hypertension or heart failure dosing may not apply directly to Long Covid, leaving the ideal regimen unclear.
- Mechanistic nuances: While its immunomodulatory and anti-inflammatory properties appear promising, the precise pathways in Long Covid remain under investigation.
- Long-term outcomes: Extended use for Long Covid has not been fully studied, making it difficult to predict any late-emerging side effects or sustained benefits.
- Blocks ACE enzyme: Prevents conversion of angiotensin I to angiotensin II, reducing vasoconstriction.
- Modulates immune function: May curtail excessive inflammatory responses through altered cytokine signaling.
- Decreases vascular resistance: Helps widen blood vessels, improving circulation and oxygen delivery.
- Stabilizes blood pressure: Maintains controlled blood pressure levels to support cardiovascular health.
- Persistent dry cough: A common reaction that may exacerbate breathing discomfort.
- Sudden hypotension: Blood pressure can drop quickly, causing dizziness or fainting.
- Angioedema risk: Swelling of face or throat, though relatively rare, requires urgent attention.
- Electrolyte imbalances: Can affect potassium and sodium levels, necessitating blood test monitoring.
- Limited large studies: Some experts question its effectiveness for Long Covid due to scarce data.
- Off-label challenges: Physicians may hesitate to prescribe it specifically for Long Covid without formal guidelines.
- Ongoing debate: Researchers differ on whether its main benefits stem from anti-inflammatory or purely vascular effects.
- Individual variation: Responses can differ among patients, fueling mixed perspectives on its suitability.
Patient views
Experiences
- Some patients find the theoretical anti-inflammatory benefits of ACE inhibitors, like captopril, intriguing.
- A few patients appreciate the potential for ACE inhibitors to address inflammation-related symptoms in chronic conditions.
- The idea of targeting overactive immune responses with captopril is seen as promising by some.
Challenges
- Many patients report severe side effects, like dangerously low blood sodium (hyponatraemia).
- Some experienced extreme drops in blood pressure, leading to discontinuation of the drug.
- Patients highlight a lack of clear warnings about risks like hyponatraemia.
- Some feel the treatment worsened their overall health or caused new issues.
Tips
- Patients recommend discussing all potential risks with a knowledgeable doctor.
- Monitoring hydration and sodium levels is advised to avoid complications.
- Starting with a low dose and increasing cautiously may help reduce risks.
- Patients suggest researching alternative treatments if side effects occur.
To calculate the reported effectiveness for a patient view, the model first analyses whether it can be ascertained that the person writing the review has had direct experience of the treatment for themselves or a loved one. If so, it then uses sentiment analysis to rate their view from 1-5 on how effective this treatment was for them, with 1 being the least effective, and 5 the most effective.
Patient view
It was prescribed for me, but dropped my blood pressure too much so it was stopped.
July 2024 • Turnto Comment
Patient view
Over-exertion while taking an ACE inhibitor came close to killing me twice, as it led to dangerously-low blood sodium (hyponatraemia), putting me in hospital the second time. Just a little lower and I could have died. I realised then that the saying "Hard work never killed anyone" was untrue.
December +47195 • Phoenix Rising Forum
What and who it targets
Cardiovascular complications
Addresses heart-related symptoms effectively.
Kidney strain cases
Protects kidney function under stress.
Hypertension patients
Regulates elevated blood pressure levels.
Fatigue with heart strain
Improves energy by reducing heart load.
Relevant research
How much evidence on this?
- Few studies directly assess captopril for long COVID.
- Research spans 2021–2024, mostly theoretical or exploratory.
- Focus on renin-angiotensin system and cardiovascular effects.
- Limited clinical trials specifically for long COVID.
Research focusing on
- Captopril may affect cardiovascular injuries in long COVID.
- Renin-angiotensin system plays a key role in pathogenesis.
- Long COVID linked to organ damage and inflammation.
- Researchers exploring phase-specific RAS inhibition.
What needs more research?
- Direct efficacy of captopril for long COVID symptoms.
- Long-term safety in long COVID patients.
- Optimal dosage and timing for treatment.
- Mechanisms of captopril's impact on non-cardiovascular symptoms.
- ⬤ Minimal research: Very little scientific study exists, with no or very few peer-reviewed studies. Insufficient data for conclusions.
- ⬤⬤ Limited research: Few studies exist, mostly small trials or case reports. Findings are preliminary and lack strong validation.
- ⬤⬤⬤ Moderately researched: Multiple studies, including mid-sized trials, exist. Some findings are replicated, but more research is needed.
- ⬤⬤⬤⬤ Well-researched: Supported by substantial evidence, including at least one large trial or meta-analysis.
- ⬤⬤⬤⬤⬤ Extensively studied: Numerous large studies and meta-analyses exist. Findings are widely accepted with strong scientific consensus.
Research
This study examined whether using ACE inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs), such as Captopril, affects kidney health and overall mortality in people with and without long COVID. Researchers analyzed real-world data from over 18,000 long COVID patients and 181,000 non-long COVID patients, comparing those who used ACEIs/ARBs to those who did not.
The study found that ACEI/ARB use did not increase the risk of acute kidney injury (AKI) or chronic kidney disease (CKD) in either long COVID or non-long COVID patients. However, long COVID itself was linked to higher risks of CKD and all-cause mortality. Interestingly, ACEI/ARB use showed a protective effect against all-cause mortality in non-long COVID patients.
For individuals with long COVID, this study highlights the increased risks of kidney disease and mortality associated with the condition, but reassures that ACEI/ARB treatments like Captopril do not worsen kidney health. This information can help patients and caregivers make informed decisions about managing long COVID and its complications.
The study is reliable as it uses a large dataset and employs robust statistical methods, such as multivariable regression models. Published in the Clinical Kidney Journal, a reputable source in nephrology, the findings are relevant for understanding kidney-related risks in long COVID patients.
July 2024 • Clinical kidney journal
Research
This paper explored how Long COVID affects various organs and systems in the body, such as the respiratory, cardiovascular, and neurological systems. It focused on the role of the renin-angiotensin system (RAS) in the development of Long COVID and discussed potential treatment approaches.
The study found that the renin-angiotensin system (RAS) plays a significant role in the pathogenesis of Long COVID, similar to its role in acute COVID-19. It highlighted that targeting the RAS could be a promising therapeutic approach for managing Long COVID symptoms.
For individuals living with Long COVID, this paper suggests that treatments targeting the renin-angiotensin system, like Captopril, might help alleviate symptoms. It provides hope for more targeted therapies that address the underlying mechanisms of the condition.
As a systematic review published in a reputable journal, this paper is reliable. It synthesizes existing research on Long COVID and the RAS, making it a valuable resource for understanding potential treatment pathways.
May 2022 • Molecules (Basel, Switzerland)
Accessibility
- ⬤ Extremely Difficult to Access: Rare, experimental, or highly specialized. Requires multiple referrals, long wait times, travel, and strict follow-up.
- ⬤⬤ Difficult to Access: Limited to select centers with moderate barriers. Requires referral, potential travel, and wait times of weeks to months.
- ⬤⬤⬤ Moderately Accessible: Available in larger hospitals or clinics. Requires a basic referral, with moderate wait times and some coordination.
- ⬤⬤⬤⬤ Easy to Access: Widely available in most clinics. Minimal referral, short wait times, and simple preparation or follow-up.
- ⬤⬤⬤⬤⬤ Trivial to Access: Easily found in pharmacies or clinics. No referral needed, minimal wait, and straightforward access.
- ⬤ Up to $100
- ⬤⬤ Up to $500
- ⬤⬤⬤ Up to $2000
- ⬤⬤⬤⬤ Up to $10,000
- ⬤⬤⬤⬤⬤ More than $10,000
Method to access
- Obtain a prescription from a healthcare provider.
- Purchase at local pharmacies or online platforms like GoodRx or Amazon Pharmacy.
- Consult a doctor for potential off-label use for Long Covid.
Cost
- In the US, prices range from $7 to $36 for a 30-day supply, depending on dosage and pharmacy.
- Generic versions are significantly cheaper than brand-name Capoten.
- International prices may vary but are generally affordable.
Insurance cover
- Generic Captopril is covered by most Medicare and insurance plans in the US.
- Coverage may vary internationally, but it is often included in standard health insurance plans.
Locations
- Available at most local pharmacies in the US, including CVS and Walgreens.
- Online pharmacies like GoodRx and Amazon Pharmacy.
- Widely available in hospitals and clinics globally.
Frequently asked questions
Explore other treatments
It's a lot of information, isn't it?
Turnto's personal AI Assistant can help you figure out what this all means for you
© 2026 Turnto
